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Abstract
Background: Celiac Disease occurs at a 5–10 fold greater prevalence in patients with type-1 diabetes (T1D), despite
this increased risk, there is limited objective evidence regarding the impact of a Gluten-Free Diet (GFD) in the large
proportion of asymptomatic (30–70 %) patients with both autoimmune diseases. Given the requirements and
intricacies inherent to each condition, we describe the rationale and design a dietary curriculum specifically
addressing the educational requirements for children and adults with CD and diabetes as part of the CD-DIET
Study.
Methods and design: The CD-DIET Study (Celiac Disease and Diabetes - Dietary Intervention and Evaluation Trial)
is a multicenter randomized controlled trial aimed at evaluating the safety and efficacy of a GFD in patients with
asymptomatic celiac disease and T1D on key diabetes and patient-centered outcomes.
Discussion: Key dietary components of the trial include a description and evaluation of food consumption patterns
including glycemic index and glycemic load, novel assessments of gluten quantification, and objective and
subjective measures of GFD adherence. This dietary curriculum will establish rigorous guidelines to assess
adherence and facilitate evaluation of a GFD on metabolic control, bone health and patient quality of life in
patients with CD and diabetes.
Trial registration Number: NCT01566110. Date of Registration: March, 2012.
Background
Celiac Disease (CD) is an autoimmune disease character-
ized by damage to the small intestine, triggered by gluten
ingestion from wheat, rye and barley and their derivatives
in genetically susceptible individuals [1, 2]. Currently the
only treatment for CD is a lifelong adherence to the
gluten-free diet. CD prevalence in T1D patients approxi-
mates 5-7 %. Despite this increased risk, many health care
professionals struggle as to the optimal approach to man-
aging CD in Type 1 Diabetes (T1D). The diagnosis of
patients who present with symptomatic CD, including
malabsorption and obvious pathology upon biopsy, re-
mains straightforward, with improvements noted on a
gluten-free diet. Many patients identified by screening,
however, tend to be asymptomatic [3, 4]. Evidence is
inconclusive as to whether the benefits of screening and
potentially treating asymptomatic individuals outweigh
the harms of managing a population already burdened
with an established chronic illness.
The CD-DIET Study (Celiac Disease and Diabetes -
Dietary Intervention and Evaluation Trial) is a multicenter
randomized controlled trial aimed at evaluating the safety
and efficacy of a GFD in patients with asymptomatic celiac
disease and T1D over 1 year. Key outcomes include the
impact of GFD on diabetes control (HbA1c), bone health,
blood glucose variability, and patient centered measures
including quality of life and self-perceived health. Dietary
outcomes will include description and evaluation of food
consumption patterns including glycemic index and load,
dietary characteristics including gluten quantification, and
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highlight objective and subjective measures of GFD adher-
ence. As a consequence, a de-novo dietary curriculum
specifically addressing the educational requirements for
GFD and T1D was developed to study dietary adherence
and facilitate evaluation of key dietary components and
their impact on study outcomes (Fig. 1).
An additional challenge of this trial relates to potential
difficulties with individual adherence to their assigned
dietary group. As such, significant effort was invested in a
patient and family centered dietary experience supported
by dietitians with extensive knowledge of diabetes, and a
curriculum with subjective and objective assessment for
dietary quality and gluten content. A de novo study diet-
ary handbook was also created for the study, with sections
focusing on adaption to the GFD highlighting situational
approaches and providing gluten-free diabetes-specific
nutritional tables for carbohydrates and glycemic index.
This paper describes approach and details of the dietary
curriculum implemented as part of the CD-DIET study to
address the needs and challenges of living with asymptom-
atic CD and T1D.
The challenge of T1D & CD: dietary quality and education
CD is a unique condition since dietary modification is
the only currently recommended and effective treatment.
Type 1 diabetes is a challenging condition requiring daily
efforts to balance meals, activity, and insulin to maintain
adequate metabolic control. It is important to assess the
impact of CD on dietary quality and composition as
transition to a GFD may pose a risk of nutritional imbal-
ances and/or deficiencies. Dietary inadequacies have been
reported to be common with CD. This may be inherent
to the diet but also as a result of habitual poorer
choices [5–7], although it has been shown that imbal-
ances from the GFD are no different than the imbal-
ances noted in the healthy population [8]. Gluten-free
foods available in Canada, analyzed for macro/micronu-
trient composition were found to be lower in fiber, iron,
calcium, protein, folate and vitamin D and higher in total
carbs, fat and sugar [5, 6, 9, 10] than products containing
gluten. Similar imbalances including higher fat, lower fiber
and nutrient intakes have been noted in children and
adults with T1D [11, 12]. Compared to their gluten con-
taining equivalents, processed GF foods including breads,
cereal bars and pasta have been reported to be higher in
total carbohydrates, lower in protein and higher in so-
dium, saturated fat and cholesterol [13]. Additionally,
many starchy GF foods were noted to have variable min-
eral content and high glycemic index [14]. From a Canad-
ian context, both the Canadian Celiac Association (CCA)
and the Canadian Diabetes Association (CDA) offer access
to pertinent information including nutritional and finan-
cial support strategies for each medical condition. How-
ever there are limited all-encompassing dietary advice/
resources catered to needs of individuals living with the
double diagnosis of CD and T1D. A comprehensive litera-
ture review including PubMed, Medline, University of To-
ronto Libraries and various Internet websites investigated
what resources are available on the subject. Our research
found that the current available literature is limited in pro-
viding effective meaningful and tangible resources, tai-
lored to address the short and long term needs and
challenges of both conditions, particularly of asymptom-
atic patients with CD and T1D. At our center we have a
unique experience of having the opportunity to follow this
population affected by a double diagnosis of Type 1 dia-
betes and Celiac Disease, combined with an expertise and
specialization in this field. A comprehensive curriculum
has been developed to address the perceived and noted
challenges as practitioners, patients and the literature.
Impact of CD in T1D: Quality of life (QOL)
In studies of existing chronic conditions such as diabetes,
which involve mandatory daily routines to remain safe,
and daily challenges which require problem solving, it is
important to evaluate the impact of the double diagnosis
(CD and T1D) that may further negatively impact quality
of life (QOL). Areas of negative impact in maintaining a
GFD have been described as follows: cost maintaining a
GFD, and extend to socializing GF including dining out,
impact on family, career, travel and religious practices
[15–18] and the corresponding negative psychological
symptoms and negative emotions [19, 20]. The benefit
of the gluten-free diet (GFD) on QOL in asymptom-
atic screened-detected CD patients remains contro-
versial [20–23]. Asymptomatic patients with CD report
Fig. 1 Primary and Secondary Outcomes for CD-DIET (Celiac and
Diabetes-Dietary Intervention and Evaluation Trial)
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better self-perceived health and less concern with their
disease prior to dietary modification [24, 25], and over half
of patients following a GFD for more than 5 years have
reported QOL as excellent or very good [26].
Given these challenges and our clinical experience
with our population, a key element of the dietary curricu-
lum is to address all the challenges through education.
Information is provided in a supportive, encouraging and
individualized manner with regular visits where patients
are asked to bring in labels and practice problem solving.
The Book’ Your Guide to Well Being: Managing Celiac
Disease and Diabetes’ is written in a modular form so that
patients and their families could refer to various sections
that they find pertinent. The book addresses and provides
tangible and concrete guidance on living with Type 1 and
CD. It addresses in detail all aspects of social life and pro-
vides practical advice for incorporating a GFD while eating
out, traveling, celebrations, management at school, univer-
sity, and the workforce. A resource list including support
groups, helpful websites, associations and organizations, a
detailed list of GF foods with their macro and micronu-
trient contents including GI is available to support the
practical day to day life of CD and T1D. To limit financial
barriers, all patients on a GFD are provided with a
monthly stipend for their groceries.
Dietary assignment in a clinical trial: opportunities and
challenges
Symptomatic patients who follow a GFD experience an
improvement in symptoms and therefore following a GFD
is meaningful. However it is less clear if there are any
related benefits to asymptomatic CD patients with T1D
who follow a GFD. The CD-DIET Study represents an op-
portunity to evaluate the impact of a GFD on asymptom-
atic patients with CD. This is a randomized, controlled,
multicenter, dietary intervention study in pediatric and
adult diabetes centers across Ontario, Canada, that is
based on an intention to treat. The study consists of a
comprehensive dietary interview with defined subjective
and objective parameters. It is designed to address the
educational and psychosocial needs and challenges of
living and thriving with both conditions: CD and T1D.
CD-DIET is designed to evaluate the efficacy and
safety of the gluten-free diet (GFD) in patients with asymp-
tomatic biopsy confirmed CD and T1D. Patients (ages 8–
45) will be randomly assigned to a GFD or continue with
their usual diabetes gluten containing meal plan [27] (Fig. 2
study flow diagram). Patients will be followed-up every
3 months where Visit 1 is randomization, Visits 2,3,4 and 5
as 3, 6,9, and 12 months respectively from randomization.
We anticipate that this may be a challenge as adherence to
dietary advice is reported to be the lowest of all treatment
types [28] with a range of 36-96 % as strict adherence [15].
Designing the dietary protocol takes into account 3
key components to successful adherence to the GFD, as
identified by the literature and our experience: under-
standing of the GFD, ability to maintain a GFD while
away from home and membership in a celiac support
group [23]. These factors not only are met via the guide
developed and described above but have been embedded
into the dietary curriculum with opportunities to evalu-
ate knowledge and adherence at every visit. Therefore a
robust dietary curriculum which includes a detailed
Fig. 2 Flow diagram illustrating screening and eligibility for
Intervention. Mahmud et al BMJ Open 2015
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educational plan of what and when information will be
relayed, with opportunities for assessment and evalu-
ation of dietary quality, food consumption patterns and
adherence, are key elements to the success of this study.
The dietary curriculum is planned to detect any dietary
deficiencies and imbalances of macro and micronutrients
as well as dietary fiber, calcium, vitamin D and iron using
ESHA, a Food Processor with Nutrition Analysis software.
The study will also include gluten consumption patterns
of the subjects enrolled using the Osborne formula [29].
“Your guide to Well Being: Managing celiac and Dia-
betes” was designed specifically for the intervention arm
(GFD) to address the intricate educational and social needs
of both CD and diabetes. It was written in a modular form
as an easy to use guide with topics ranging from explaining
the diagnosis and managing a GF home to special consid-
erations and travel with T1D. Figure 1 depicts an overview
of the dietary curriculum with the study visits.
The Role of the dietitian in this study is identified as
supporting the subjects to the arm that they are random-
ized to, but not intended to intensify diabetes manage-
ment. Subsequently adherence in this study is defined as
the ability to follow the prescribed diet. Dietary adherence
will be assessed at each clinic visit both objectively and
subjectively.
Components dietary assessment and adherence
3 major components of assessment for adherence were
identified which include subjective and objective mea-
sures: 1. a comprehensive dietary interview with alter-
nating 3 day food records and typical day recalls. 2.
Application of Celiac Dietary Adherence test (CDAT)
and 3. Serology –TTG IgA titres.
Objective measures of assessment
The objective measures in the dietary assessments in-
clude (Fig. 3):
1. A 3 day food record will be collected and clarified.
Subsequently, records will be sent to central analysis
where nutrient intake will be analyzed using the
computer based ESHA food processor which
contains a wide data base capable of analyzing over
160 food nutrient components and compare to
DRIs. The analysis will include macronutrient
distribution to be compared to CDA practice
guidelines and specific nutrients including calcium,
iron, vitamin D and fiber. Alterations in
macronutrients, vitamins and minerals have been
associated with imbalances and/or deficiencies with
the GFD [5–8]. Additionally, Glycemic index (GI)
and glycemic load (GL) of mixed meal will be
calculated and analyzed for both GFD and GCD.
In this study we are also planning to describe the
food consumption patterns of our population with
dietary gluten. This will be done by multiplying the
plant proteins of overt gluten sources by a factor of
0.8 [29]. This is a relatively novel approach in North
America in relation to its application to dietary in-
take. Our findings from a previous study show that
this approach to dietary gluten estimation is reason-
able and valid (29). Dietary gluten for the GFD group
will be estimated by using the maximum 20 ppm
standard as defined by Health Canada’s labelling regu-
lations [30].
2. Celiac dietary Adherence Test (CDAT)- a 7 item
questionnaire that has been demonstrated to have a
highly predictive value (88 %) for verifying compliance
with the GFD in adults, as compared to TTG IgA and
dietary evaluation [31]. It will be administered to the
subjects randomized to the GFD at every visit after
randomization (visits 2–5) (Fig. 4).
3. Tissue Transglutaminase IgA Antibody Assay-TTG
IgA – we anticipate that if subjects are adherent,
serology will normalize or decrease with subjects
randomized to the GFD and remain elevated for
subjects randomized to the GCD. Blood sample will
be taken from both groups at visits 3 and 5.
Fig. 3 methods of Assessment for GFD/GCD arms
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Subjective measures of assessment
The subjective measures in the dietary assessments in-
clude (Fig. 3):
1. Comprehensive dietary interviews to also include
3 day food records (at visits 1, 3 and 5) and a typical
day recall (at visits 2, 4) (Fig. 1). In the absence of a
3 day food record a typical day recall will be taken.
Through the records, the dietitian will assess for the
presence of dietary gluten and/or hidden sources of
gluten.
2. Ranking: At the end of every dietary interview a
global ranking of adherence will be applied by the
dietitian. A ranking of ‘expectations’ will be applied
to the subjects on the GFD arm. The ranking will
range from ‘Below Expectations’ - minimal
understanding of GFD concepts and inability to
distinguish carbohydrate containing foods, to
‘Meeting Expectations’ – with the GFD and ability
carb count, and ‘Above Expectations’ – advanced
understanding of the GFD, seeks out additional
information about GF carb sources and
demonstrates an interest in the curriculum. A
ranking of gluten inclusion and exclusion will be
applied to the GCD arm. The ranking will range
from “Complete inclusion of gluten containing (GC)
foods to ‘Some restriction of GC foods’ to a ‘strict
restriction of GC foods’.
Fig. 4 CD-DIET Visit components
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3. Subject’s own self report: Subjects will also have an
opportunity to evaluate their own adherence with
the diet that they have been randomized to from
‘strict’ to ‘partial’ to ‘none’ adherent.
CD-DIET study dietary overview: methods and
design
Subjects aged 8 to 45 years old with established T1D
and biopsy confirmed asymptomatic CD will be random-
ized to treatment with GFD for one year or continue with
their usual GCD as described (Refer to Figs. 2 and 4) [27].
Dietitian visits
All subjects on both arms of the study will have five visits
with a trained dietitian. Worksheets specific to each arm
and visit have been designed to ensure consistent collec-
tion of information, and uniform parameters for assess-
ment and education. All worksheets will be filled out by
the dietitian at every visit. All participants will fill out food
records (two weekdays and 1 weekend day) for visits 1, 3
and 5 (at initial assessment, 6 month and 12 months).
Food records will be sent to ESHA, and will be reviewed
with the participants at their following visit (visits 2 and 4,
3 and 9 months, respectively). Glycemic Index (GI) and
Glycemic load (GL) will be calculated to describe the diet-
ary carbohydrates of each arm using glucose as a refer-
ence. GI of mixed meals per day will be ranked as: Low GI
≤55, Medium GI 56–69 and High GI ≥70. Similarly GL
per day will be ranked as: Low GL <80, Medium GL 80–
120 and a high GL >120 [32]. Dietary gluten evaluation
will be performed by using the Osborne formula for all
subjects at baseline. Twenty ppm will be applied to the
GFD arm as per Health Canada’s definition of GF claims.
A typical day intake is incorporated into the dietary
interview at visits 2 and 4 (3 and 9 month visit respect-
ively). All records will be assessed for dietary exclusion
or inclusion of gluten. At visits 2–5 (3,6,9, and
12 months) inclusive all participants will complete with
the dietitian a 'self-report' questionnaire designed to as-
sess their comfort (both groups) and understanding of
their assigned diet.
Height, weight, BMI and z-scores
Regular monitoring of anthropometric parameters will
be performed to assess safety. Height and weight will be
obtained at every clinic visit and BMI and z-scores will
be derived from those measurements. Level of activity
will be ranked as per The Canadian Physical activity
guidelines (www.csep.ca/) (Fig. 1).
Dietary adherence
Dietary adherence will be assessed at each visit following
the baseline visit. Adherence assessment will be classi-
fied as objective and subjective as described earlier.
Subjective and objective assessment of adherence will
include food records collected at visits 1, 3 and 5
(randomization, 6 and 12 months) and a typical day in-
take at visits 2 and 4 (3 and 9 months) for both groups.
All records will be evaluated for inclusion and exclusion
of gluten. In addition, food records will be analyzed via
ESHA, dietary food processor. GI/ GL and gluten con-
tent will be assessed at baseline, 6 and 12 months in
both arms. For the intervention group, the adherence to
GFD will be further assessed by the application of the
Celiac Dietary Adherence Test (CDAT). Additionally,
TTG-IgA titers will be measured at 6 (Visit 3) and
12 months (Visit 5) visits to asses GFD/GCD
compliance.
After randomization (visit 1) at visits 2 to 5, both study
groups, intervention and control, will be interviewed to
assess and document adverse events including severe
hypoglycemia requiring assistance, hospitalization, any
changes in non-insulin medications, supplements and vi-
tamins from previous visit. HbA1c and TTG will be col-
lected at visits 1, 3 and 5 for both arms. GISS and
CDAT questionnaires will also be completed only for
intervention group, at each visit.
A trained dietitian from the leading site will train iden-
tified dietitians from the partner sites using standardized
educational material and a detailed manual of operations
describing the goals objectives of the dietary curriculum
and the steps for the dietary interview at each visit. The
standardized tools will be used to maintain quality and
consistency of dietary education and collection of
information.
Intervention group
Visit 1: The dietary interview will consist of a compre-
hensive nutritional assessment followed by the GFD
education. “Your Guide to Well-being: Managing Celiac
Disease and Diabetes” is a resource manual, divided into
modules, that was specifically designed for this popula-
tion to address the complex dietary nature of living with
both CD and T1D. This resource as well as "Pocket Dic-
tionary of Ingredients" and 'Checking Ingredient List' by
the Canadian Celiac Association will be provided to the
participants along with the GFD education. Participants
will be directed to online resources such as Apps that
will help and guide them in determining presence of glu-
ten in food, as well as locations of gluten free restaurants
and stores in their vicinity. At the end of the education
session an assessment will be carried out using food la-
bels for the comprehension of the GFD, carb counting
skills and current diabetes management. Three day food
records will be collected, clarified and sent to central
analysis for ESHA (Elizabeth Stewart Hands and Associ-
ates) processing.
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Control group
Visit 1: The dietary interview will consist of a compre-
hensive nutritional assessment including on how well
the subjects are managing their current diet and ensur-
ing consumption of GC foods. Food labels will be used
to assess carbohydrate counting skills. Three day food
records will be collected, clarified and sent to central
analysis for ESHA processing.
A 4 week follow-up call will be done in both groups to
support, address questions and concerns, document any
changes in non-insulin medications, supplements and
vitamins and document adverse events including severe
hypoglycemia requiring assistance.
Follow-up visits 2, 3 and 4 (Months 3, 6 and 9)
Intervention group
The dietary interview will address any gaps in education;
provide nutritional support and reinforcement of GFD
topics and modules, as required. Subject's food records
analysis from visit 1 will be reviewed for imbalances and
deficiencies in macronutrients as per Canadian Diabetes
Association guidelines and against DRIs. A plan to ad-
dress any issues or concerns will be implemented and a
“Typical Day Intake” will be performed to assess for glu-
ten exclusion and/or inclusion. Subjects with the
dietitian will complete a 'self-report' questionnaire de-
signed to assess their comfort with their assigned diet.
The dietitian will rank the subjects adherence using spe-
cific criteria, see Fig 3. Three day food records will be
provided for visit 3.
Control group
The dietitian interview will aim to support current diet-
ary management. Subject's food records analysis from
visit 1 will be reviewed for imbalances and deficiencies; a
plan to address any issues or concerns will be imple-
mented. A “Typical Day Intake” will be performed to assess
for gluten exclusion and/or inclusion. Subjects with the
dietitian will complete a 'self-report' questionnaire designed
to assess their comfort with their assigned diet. The
dietitian will rank the subjects adherence using specific
criteria, see Fig 3. Three day food records will be provided
for visit 3.
At 3 (Visit 2) and 9 months (Visit 4) a “Typical Day
Intake” interview will be performed as part of the diet
interview and food records will be provided for next
visit. At visit 3 and 5 (6 and 12 months) in addition to
the dietary interview, food records will be collected and
sent to central analysis for ESHA processing. Handouts
specific to each group (GFD/GCD) have been designed
to address the possible dietary deficiencies or imbalances
in macronutrients as well as fiber, iron, calcium and vita-
min D.
Conditional telephone contact (Month 7)
This telephone call will apply to subjects who are found
to be non-adherent (as per TTG IgA results from Visit
3) to their assigned diet. For both groups: dietitian will ad-
dress follow-up questions and concerns, barriers to dietary
adherence, document any changes in insulin regimen or
in non-insulin medications, supplements and vitamins,
document adverse events including severe hypoglycemia
requiring assistance.
Visit 5 (Month 12)
For both arms this visit will entail all of the details as
per visit 3 (month 6) visit. The dietitian will conduct an
exit interview consisting of 7 questions for GFD and 4
questions for the GCD. Subjects assigned to the GCD
will be asked if they would like to follow the GFD.
Outcome assessments
CDAT and TTG and Dietitian’s ranking
We anticipate that the subjective ranking by the dietitian
will correlate with the subject’s TTG, CDAT and self-
report in both arms. We also anticipate that the average
GI and the GL content of the GFD will be higher than
the GCD due to the nature of some of the GF foods
which tend to be more refined higher in carbohydrate
and contain less fiber than the GC equivalents. The dif-
ference in GI and GL between the groups may also ex-
plain the possible BG variability in both groups as will
be documented with (continuous glucose monitoring
(CGM)).
Changes in dietary intervention assignment (cross-overs)
In cases of symptom presentation as defined by Mahmud
et al. [28] subjects will be crossed over into the GFD.
Power calculation and statistics:
The outcome measure used to calculate sample size will
be the change in HbA1c level from baseline to month 12.
Based on previous work, in a non-randomized compari-
son of HbA1c levels over time in type 1 diabetes patients
with asymptomatic CD who received a GFD versus pa-
tients with type 1 diabetes alone, an increase in HbA1c of
8.3 ± 1.1 % to 8.9 ± 1.5 % was observed.10 As such, 91 eva-
luable individuals per group are required to provide 80 %
power to detect a difference of at least 0.5 % at the 0.05
level of significance. The enrolment of 200 participants
will allow for a non-evaluable rate of about 10 %. To reach
the recruitment target of 200 individuals, approximately
5000 patients with an established diagnosis of type 1 dia-
betes will be screened for asymptomatic CD. Efficacy ana-
lyses will be performed on the intent-to-treat population
consisting of all randomized participants.
The primary efficacy outcome, the change in HbA1c
at 12 months, will be analyzed using an analysis of covari-
ance (ANCOVA) model that includes adjustment for
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baseline HbA1c, age groups and investigative sites. Treat-
ment effect will be quantified using the point estimate, the
two-sided 95 % CI, and associated p value. Significant
effect will be declared at the 5 % significance level.
Severe hypoglycemic episodes over time will be ana-
lyzed as Poisson counts using the generalized estimating
equations approach to account for correlation among re-
peated measures within an individual. The QOL data over
time will be analyzed by means of a linear mixed effects
model including factors for treatment, investigative sites,
age groups, and baseline QOL scores. BG variability and
change in Z-score at the lumbar spine will be analyzed
using the ANCOVA approach. The Statistical Analysis
System (SAS) procedures GENMOD, MIXED and GLM
in SAS V.9.2, will be used to perform the respective
analyses.
Patient consent: Obtained.
Ethics Approval: Research Ethics Board Hospital for
Sick Children, University of Toronto and at all recruit-
ment sites.
The CD-DIET study data safety and monitoring board
will perform regular reviews of collected safety and effi-
cacy data. The protocol was peer reviewed by the JDRF.
Trial organization
– JDRF-CCTN (Juvenile Diabetes Research
Foundation – Canadian Clinical Trials Network) –
financial and organizational support
– Robarts Clinical Trials and Sickkids – Monitoring,
safety and adverse events coordination
– Group Organization – Paediatric and adult
endocrinologists, gastroenterologists, diabetes
dietitians, and research coordinators in each of
different sites.
Discussion and dissemination
The CD-DIET study is a large scale clinical trial that will
further contribute to the pool of knowledge and novel
implications to the treatment of asymptomatic celiac
disease and TID. The dietary curriculum will be coordi-
nated across all centers by the main site dietitian, using
standardized educational materials and a manual of
operations. Both pediatric and adult patients will be
randomized to a GFD or GCD. Adherence to the diets
will be determined from the dietary interview, TTG-IgA
blood tests and CDAT (GFD) and subjects’ self-report.
CDAT is highly correlated with Standardized Dietician
Evaluation (SDE) and even superior to TTG IgA serology
with regards to GFD adherence [31]. The Canadian con-
text to the study is important, as the 2013 Canadian Dia-
betes Association’s clinical practice guidelines suggests a
targeted symptom based screening approach [33]. While
the literature supports the implementation of a GFD in
symptomatic CD and T1D patients, it is less clear as to
the benefits for asymptomatic patients. Our curriculum
was established in concurrence with the current literature
and is designed to address a number of issues: the limited
educational literature the challenges associated with diet-
ary quality and adherence and the implicated social
challenges of a GF lifestyle in addition to T1D and. Partici-
pants will be supported by dietitians throughout the study
and subjects on the intervention group and later the
control group will have to have access to ‘Your Guide to
Well-being: Managing Celiac disease and Diabetes' a re-
source specifically designed to address the nutritional in-
tricacies and related challenges of both conditions: CD
and T1D.
The dietary quality of the GFD will be assessed
through food records and interviews. The literature reports
that GF equivalents tend to be lower in micronutrients and
fibre, but higher in calories, fat and sodium [5, 13]. The
participant’s diets will be evaluated for deficiencies and
imbalances of macronutrients and micronutrients. We will
assess the quantity and quality of carbohydrate intake using
the glycemic index as well as glycemic load and calculate
dietary gluten in our subject population. Dietary gluten
quantification was previously demonstrated in Europe and
applied to one of our smaller pilot studies with some limi-
tations inherent to methodology and with the Canadian
and American nutrient databases. We have described a
method to help apply the Osborne calculation in North
America [11] and plan to correlate adherence to gluten
consumption and describe our population’s consumption
patterns as it relates to CD and T1D.
Participants will also have the opportunity to report
their adherence to the diet that they are randomized to
through a ‘self-report’ questionnaire from ‘strict’ to ‘par-
tial’ to ‘non’ adherent [34]. Although some studies show
that patients overestimate adherence to GFD and that
reliability of self-reports decreases with time on a GFD
[16, 35], our previous findings show a close correlation
between self-reports and dietitians’ assessment [36].
One of the greater challenges with asymptomatic pa-
tients if that they report better QOL and health prior to
diagnosis [25]. This is likely due to the perceived burden
of novel dietary restriction.
This study will answer some of the questions with
regards to perceived benefits of GFD, especially when al-
most a third [37] of health practitioners are unsure whether
they should be recommending GFD to asymptomatic pa-
tients [38]. The study was initiated in 2012, now active at
16 centers, and it is anticipated that results will be available
by 2016.
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